Formosa Laboratories Inc (4746) - Total Liabilities
Based on the latest financial reports, Formosa Laboratories Inc (4746) has total liabilities worth NT$4.99 Billion TWD (≈ $157.11 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Formosa Laboratories Inc to track the company's year-over-year net asset growth rate.
Formosa Laboratories Inc - Total Liabilities Trend (2009–2024)
This chart illustrates how Formosa Laboratories Inc's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Formosa Laboratories Inc to measure how efficiently the company converts operating cash flow to free cash.
Formosa Laboratories Inc Competitors by Total Liabilities
The table below lists competitors of Formosa Laboratories Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boyaa Interactive International Limited
F:1BY
|
Germany | €562.55 Million |
|
Bin Chuan Enterprise Co Ltd
TWO:1569
|
Taiwan | NT$3.53 Billion |
|
GTM Holdings Corp
TW:1437
|
Taiwan | NT$5.45 Billion |
|
GomSpace Group AB
ST:GOMX
|
Sweden | Skr358.66 Million |
|
Ananti Inc
KQ:025980
|
Korea | ₩832.68 Billion |
|
Atomera Inc
NASDAQ:ATOM
|
USA | $2.71 Million |
|
Eureka Group Holdings Ltd
AU:EGH
|
Australia | AU$152.71 Million |
|
Frauenthal Holding AG
VI:FKA
|
Austria | €204.49 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Formosa Laboratories Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 4746 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.65 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Formosa Laboratories Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Formosa Laboratories Inc (2009–2024)
The table below shows the annual total liabilities of Formosa Laboratories Inc from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$5.25 Billion ≈ $165.36 Million |
-3.27% |
| 2023-12-31 | NT$5.43 Billion ≈ $170.95 Million |
+9.52% |
| 2022-12-31 | NT$4.95 Billion ≈ $156.09 Million |
+12.22% |
| 2021-12-31 | NT$4.41 Billion ≈ $139.09 Million |
-11.70% |
| 2020-12-31 | NT$5.00 Billion ≈ $157.53 Million |
-2.93% |
| 2019-12-31 | NT$5.15 Billion ≈ $162.29 Million |
+23.60% |
| 2018-12-31 | NT$4.17 Billion ≈ $131.30 Million |
+32.68% |
| 2017-12-31 | NT$3.14 Billion ≈ $98.96 Million |
+19.39% |
| 2016-12-31 | NT$2.63 Billion ≈ $82.89 Million |
-12.13% |
| 2015-12-31 | NT$2.99 Billion ≈ $94.33 Million |
+12.76% |
| 2014-12-31 | NT$2.66 Billion ≈ $83.65 Million |
+7.27% |
| 2013-12-31 | NT$2.48 Billion ≈ $77.99 Million |
+4.83% |
| 2012-12-31 | NT$2.36 Billion ≈ $74.39 Million |
+91.41% |
| 2011-12-31 | NT$1.23 Billion ≈ $38.87 Million |
+25.63% |
| 2010-12-31 | NT$981.92 Million ≈ $30.94 Million |
+172.92% |
| 2009-12-31 | NT$359.78 Million ≈ $11.33 Million |
-- |
About Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. The company offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulator… Read more